Allakos - ALLK Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 2 sell ratings, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALLK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares.
View ALLK analyst ratings or view top-rated stocks.

11 Wall Street analysts have issued twelve-month price objectives for Allakos' stock. Their ALLK share price forecasts range from $13.00 to $155.00. On average, they predict the company's stock price to reach $66.80 in the next year. This suggests a possible upside of 1,011.5% from the stock's current price.
View analysts price targets for ALLK or view top-rated stocks among Wall Street analysts.

Allakos' stock was trading at $9.79 at the beginning of the year. Since then, ALLK shares have decreased by 38.6% and is now trading at $6.01.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our ALLK earnings forecast.

Allakos Inc. (NASDAQ:ALLK) announced its earnings results on Thursday, August, 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by $0.05.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven Pharmaceutical (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).

(ALLK) raised $96 million in an IPO on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Allakos' stock is owned by a variety of retail and institutional investors. Top institutional investors include Millennium Management LLC (3.44%), Federated Hermes Inc. (3.21%), Price T Rowe Associates Inc. MD (1.13%), JPMorgan Chase & Co. (1.12%), Renaissance Technologies LLC (1.05%) and Clearline Capital LP (1.02%). Insiders that own company stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, John P Mckearn, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James.
View institutional ownership trends.

Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALLK stock can currently be purchased for approximately $6.01.

Allakos (NASDAQ:ALLK) has a market capitalization of $329.61 million. The company earns $-269,860,000.00 in net income (profit) each year or ($7.39) on an earnings per share basis.

The company employs 192 workers across the globe.

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The official website for the company is www.allakos.com. The company can be reached via phone at (650) 597-5002 or via email at ir@allakos.com.